|
175
|
Safety Signal of Tacrolimus and the Risk of Hepatocellular carcinoma
|
|
Signal
|
|
|
174
|
Safety Signal of Denosumab and the Risk of Autoimmune hepatitis
|
|
Signal
|
|
|
173
|
Safety Signal of Amisulpride and the Risk of Ventricular extrasystoles
|
|
Signal
|
|
|
172
|
Safety Signal of Verapamil and the Risk of Hepatitis cholestatic
|
|
Signal
|
|
|
171
|
Safety Signal of Bisoprolol and the Risk of Atrioventricular block
|
|
Signal
|
|
|
170
|
Safety Signal of Gentamicin and the Risk of Clostridium difficile colitis
|
|
Signal
|
|
|
169
|
Safety Signal of Allopurinol and the Risk of Acute generalised exanthematous pustulosis
|
|
Signal
|
|
|
168
|
Safety Signal of Pembrolizumab and the Risk of Capillary Leak Syndrome
|
|
Signal
|
|
|
167
|
Safety Signal of Ipilimumab and the Risk of Capillary Leak Syndrome
|
|
Signal
|
|
|
166
|
Safety Signal of Capecitabine and the Risk of Metabolic acidosis
|
|
Signal
|
|
